1. 1. Li L and Wang H (2016) Heterogeneity of liver cancer and personalized therapy. Cancer Lett, 379(2): 191-197. [DOI:10.1016/j.canlet.2015.07.018]

2. Fang Y, Zhan Y, Xie Y, et al. (2022) Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC. Hepatology, 75(6): 1386-1401. [DOI:10.1002/hep.32177]

3. Pérez-Romasanta LA, González-Del Portillo E, et al. (2021) Stereotactic radiotherapy for hepatocellular carcinoma, radiosensitization strategies and radiation-immunotherapy combination. Cancers (Basel), 13(2): 192. [DOI:10.3390/cancers13020192]

4. Zhao S, Zhang Y, Lu X, et al. (2021) CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway. Int J Biol Sci, 17(13): 3608-3621. [DOI:10.7150/ijbs.64003]

5. Zhou B, Wu F, Yuan L, et al. (2015) Is Huachansu beneficial in treating advanced non-small-cell lung cancer? Evidence from a meta-analysis of its efficacy combined with chemotherapy. Evid Based Complement Alternat Med, 2015: 408145. [DOI:10.1155/2015/408145]

6. Xia J, Inagaki Y, Gao J, et al. (2020) Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the Fas-and mitochondria-mediated pathways. Am J Chin Med, 45: 1537-1556. [DOI:10.1142/S0192415X17500835]

7. Alamilla-Presuel JC, Burgos-Molina AM, González-Vidal A, et al. (2022) Factors and molecular mechanisms of radiation resistance in cancer cells. Int J Radiat Biol, 98(8): 1301-1315. [DOI:10.1080/09553002.2022.2047825]

8. Wang L, Raju U, Milas L, et al. (2011) Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells. Anticancer Res, 31(6): 2141-2148.

9. Strasser A and Vaux DL (2020) Cell death in the origin and treatment of cancer. Mol Cell, 78(6): 1045-1054. [DOI:10.1016/j.molcel.2020.05.014]

10. Xu X, Lai Y, Hua ZC (2019) Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep, 39(1): BSR20180992. [DOI:10.1042/BSR20180992]

11. Chen W, Liu Z, Zheng Y, et al. (2021) Selenium donor restricts the intracellular growth of Mycobacterium tuberculosis through the induction of c-Jun-mediated both canonical autophagy and LC3-associated phagocytosis of alveolar macrophages. Microb Pathog, 161(Pt B): 105269. [DOI:10.1016/j.micpath.2021.105269]

12. Wang D, Lin Y, Xu F, et al. (2020) SIRPα maintains macrophage homeostasis by interacting with PTK2B kinase in Mycobacterium tuberculosis infection and through autophagy and necroptosis. EBioMedicine, 85: 104278. [DOI:10.1016/j.ebiom.2022.104278]

13. Fang Y, Tian S, Pan Y, et al. (2020) Pyroptosis: A new frontier in cancer. Biomed Pharmacother, 121: 109595. [DOI:10.1016/j.biopha.2019.109595]

14. Liu J, An W, Zhao Q, et al. (2020) Hyperbaric oxygen enhances X-ray induced ferroptosis in oral squamous cell carcinoma cells. Oral Dis.

15. Sendinc E and Shi Y (2023) RNA m6A methylation across the transcriptome. Mol Cell, 83(3): 428-441. [DOI:10.1016/j.molcel.2023.01.006]

16. Niu Y, Tang G, Wu X, Wu C (2020) LncRNA NEAT1 modulates sorafenib resistance in hepatocellular carcinoma through regulating the miR-149-5p/AKT1 axis. Saudi J Gastroenterol, 26(4): 194-203. [DOI:10.4103/sjg.SJG_4_20]

17. Wang X, Wu R, Liu Y, et al. (2020) m6A mRNA methylation controls autophagy and adipogenesis by targeting Atg5 and Atg7. Autophagy, 16: 1221-1235. [DOI:10.1080/15548627.2019.1659617]

18. Xu Y, Lv D, Yan C, et al. (2022) METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modification. Cancer Cell Int, 22(1): 11. [DOI:10.1186/s12935-021-02433-6]

19. Liu L, He J, Sun G, et al. (2022) The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med, 12(5): e778. [DOI:10.1002/ctm2.778]

20. Bai Y, Wang X, Cai M, et al. (2021) Cinobufagin suppresses colorectal cancer growth via STAT3 pathway inhibition. Am J Cancer Res, 11(1): 200-214.

21. Kim GH, Fang XQ, Lim WJ, et al. (2020) Cinobufagin Suppresses Melanoma Cell Growth by Inhibiting LEF1. Int J Mol Sci, 21(18): 6706. [DOI:10.3390/ijms21186706]

22. Feng W, Zhao X, Yao Q, Li D (2022) Cinobufagin inhibits proliferation and induces apoptosis of hepatocarcinoma cells by activating apoptosis, AKT, and ERK pathways. Acta Biochim Pol, 69(4): 831-837. [DOI:10.18388/abp.2020_6245]

23. Ma X, Suo Z, Ma X, et al. (2022) Cinobufagin inhibits tumor progression and reduces doxorubicin resistance by enhancing FOXO1-mediated transcription of FCGBP in osteosarcoma. J Ethnopharmacol, 296: 115433. [DOI:10.1016/j.jep.2022.115433]

24. Yuan Z, Shi X, Qiu Y, et al. (2017) Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin. Oncol Rep, 37(3): 1815-1825. [DOI:10.3892/or.2017.5410]

25. Shi J, Yang N, Han M, Qiu C (2022) Emerging roles of ferroptosis in glioma. Front Oncol, 12: 993316. [DOI:10.3389/fonc.2022.993316]

26. Lei G, Zhang Y, Koppula P, et al. (2020) The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res, 30(2): 146-162. [DOI:10.1038/s41422-019-0263-3]

27. Chen Q, Zheng W, Guan J, et al. (2023) SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ, 30(1): 137-151. [DOI:10.1038/s41418-022-01051-7]

28. Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell, 12(8): 599‐620. [DOI:10.1007/s13238-020-00789-5]